Alamar Biosciences
ALMR
26.48
-2.20
-7.67%
Alamar Biosciences
US · ALMR
#2657 by market cap
Listed 2026
26.48
-2.20
-7.67%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.40, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Consumables is the largest reported line at 53.16% of revenue, across 3 reported segments.
- Instruments follows at 25.24%, so the top line still matters most but isn’t the whole story.
Revenue annual, last 2 years
Latest year +195.17% YoY
Margins
- Gross margin
- 56.20%
- Operating margin
- -42.22%
- Net margin
- -40.18%
Key ratios & quality
- Enterprise valuei
- 1.82B
- Altman Z-Scorei
- 2.40
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 25.14M | 74.21M |
| Gross profit | 8.61M | 41.71M |
| Selling & admin expenses | 18.94M | 35.57M |
| Research & development | 39.23M | 37.47M |
| Operating profit | -49.57M | -31.33M |
| Pretax profit | -47.06M | -29.15M |
| Tax | 13.00K | 665.00K |
| Net profit | -47.07M | -29.82M |
| Basic EPS | -1 | 0 |
| Diluted EPS | -0.71 | -0.45 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 16.16M | 19.91M | 25.05M | 26.04M | 29.43M | 33.55M |
| Gross profit | 8.58M | 11.90M | 14.84M | 14.46M | 17.72M | 20.64M |
| Selling & admin expenses | 7.61M | 9.58M | 11.75M | 13.79M | 17.43M | 19.62M |
| Research & development | 8.90M | 10.21M | 10.07M | 13.02M | 13.82M | 16.17M |
| Operating profit | -7.92M | -7.89M | -6.98M | -12.35M | -13.53M | -15.14M |
| Pretax profit | -7.02M | -7.56M | -6.91M | -20.86M | -13.29M | -13.25M |
| Tax | 0 | 440.00K | 225.00K | 464.00K | -93.00K | 94.00K |
| Net profit | -7.02M | -8.00M | -7.14M | -21.33M | -13.20M | -13.34M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.11 | -0.12 | -0.11 | -0.32 | -0.22 | -0.19 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 106.70M | 94.71M |
| Cash & ST investments | 79.36M | 30.00M |
| Inventory | 14.41M | 38.48M |
| Total assets | 149.51M | 139.99M |
| Total current liabilities | 16.59M | 23.73M |
| Short-term debt | 1.91M | 2.10M |
| Long-term debt | -- | 9.81M |
| Total liabilities | 282,922,000.00 | 298,946,000.00 |
| Total equity | -133.41M | -158.95M |
| Retained earnings | -138.96M | -168.78M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 94.71M | 141.47M | 331.38M | 317.69M |
| Cash & ST investments | -- | -- | 30.00M | 64.59M | 250.05M | 226.59M |
| Inventory | -- | -- | 38.48M | 39.93M | 45.41M | 54.13M |
| Total assets | -- | -- | 139.99M | 186.45M | 390.98M | 378.03M |
| Total current liabilities | -- | -- | 23.73M | 24.05M | 27.96M | 33.48M |
| Short-term debt | -- | -- | 2.10M | 1.60M | 2.28M | 2.48M |
| Long-term debt | -- | -- | 9.81M | 74.97M | 9.95M | -- |
| Total liabilities | -- | -- | 298,946,000.00 | 364,522,000.00 | 78,118,000.00 | 74,323,000.00 |
| Total equity | -- | -- | -158.95M | -178.07M | 312.86M | 303.70M |
| Retained earnings | -- | -- | -168.78M | -190.10M | -203.30M | -216.64M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -55.21M | -53.61M |
| Depreciation & amortization | 3.19M | 3.86M |
| Free cash flow | -58.60M | -59.99M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | 940.00K | 1.49M |
| Ending cash balance | 31.68M | 34.91M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -11.88M | -14.14M | -14.52M | -20.35M | -11.32M | -14.73M |
| Depreciation & amortization | 919.00K | 983.00K | 1.07M | 1.17M | 1.13M | 1.42M |
| Free cash flow | -13.00M | -15.47M | -17.48M | -21.13M | -15.07M | -15.37M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 164.00K | 462.00K | 624.00K | 1.80M | 205.77M | 270.00K |
| Ending cash balance | 42.57M | 52.55M | 34.91M | 69.49M | 139.22M | 126.44M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -31.48 | -20.60 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -178.91 | -38.74 |
| FCF / sales %i | -- | -- |
| Current ratioi | 6.43 | 3.99 |
| Quick ratioi | 5.22 | 1.80 |
| Debt / assetsi | 22.14 | 29.63 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -21.65 | -71.70 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -15.87 | -18.11 |
| ROA %i | -- | -- | -20.60 | -23.32 | -12.70 | -14.55 |
| ROIC %i | -- | -- | -- | -- | -14.03 | -16.60 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -38.74 | -47.94 | -47.67 | -46.90 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 3.99 | 5.88 | 11.85 | 9.49 |
| Quick ratioi | -- | -- | 1.80 | 3.50 | 9.67 | 7.41 |
| Debt / assetsi | -- | -- | 29.63 | 56.61 | 13.15 | 11.20 |
| LT debt / equityi | -- | -- | -- | -- | 15.70 | 13.13 |
| Interest coveragei | -- | -- | -71.70 | -72.28 | -63.49 | -65.07 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Consumables53.16%
Instruments25.24%
Services21.60%
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alamar Biosciences discussion 0 comments